Summary of TP53 abnormalities identified in CLL patients and their association with biologic and clinical variables
| Abnormality . | Monoallelic alterations . | Biallelic alterations . |
|---|---|---|
| Total | 23 | 47 |
| Type of defect (n) | del(17p) (3), mutation (20) | del(17p)/mutation (42), mutation/mutation (5) |
| Proportion of missense mutations, % | 100 | 67* |
| High risk: Rai stage III/IV (at the time of TP53 status examination), % (n) | 48 (10/21) | 67 (29/43) |
| P | .13 | < .001 |
| Unmutated IgVH, % (n) | 86 (18/21) | 93 (41/44) |
| P | .025 | .001 |
| 11q deletion, % (n) | 43 (10/23) | 11 (5/47) |
| P | .014 | .055 |
| Abnormality . | Monoallelic alterations . | Biallelic alterations . |
|---|---|---|
| Total | 23 | 47 |
| Type of defect (n) | del(17p) (3), mutation (20) | del(17p)/mutation (42), mutation/mutation (5) |
| Proportion of missense mutations, % | 100 | 67* |
| High risk: Rai stage III/IV (at the time of TP53 status examination), % (n) | 48 (10/21) | 67 (29/43) |
| P | .13 | < .001 |
| Unmutated IgVH, % (n) | 86 (18/21) | 93 (41/44) |
| P | .025 | .001 |
| 11q deletion, % (n) | 43 (10/23) | 11 (5/47) |
| P | .014 | .055 |
P = .003 (biallelic vs monoallelic alterations in relation to 11q deletion).
CLL indicates chronic lymphocytic leukemia.
In the subgroup del(17p)/mutation.